An exploratory study of a multi-species probiotic formulation and markers of health in a real-world oncological cohort in the time of covid
Open Access
- 26 June 2024
- journal article
- research article
- Published by Springer Nature in Inflammopharmacology
- Vol. 32 (4) , 2317-2335
Abstract
Introduction: The efficacy of cancer treatments has links to the intestinal microbiome. Mucositis is a dose-limiting intestinal pro-inflammatory side effect of cancer treatments, that increases the risk of diarrhoea, mucositis, and in severe cases, febrile neutropenia. Methods: The effect of cancer treatments on Quality of Life (QoL) was assessed using the FACT C questionnaire that included patient wellbeing and gut adverse symptoms (e.g. diarrhoea). Participants rated faecal samples via the Bristol Stool Chart. In addition, bacterial DNA was extracted from faecal samples, sequenced, and taxonomically examined. The incidence / severity of neutropenia was assessed with white blood cell and neutrophil counts. Circulating SCFAs and plasma lipopolysaccharide (LPS) endotoxin levels were recorded and correlated to intestinal mucositis. Results: Improvement in bowel function, with reduction in constipation and or diarrhoea or absence of significant disturbance to bowel function was recorded in 85% of the participants. One participant developed febrile neutropenia and two developed bowel toxicity during the study, that was unrelated to the test formulation. No significant changes in microbiota alpha- and beta-diversity at the phylum and species levels respectively from baseline to end of study treatment was observed. None of the participants had raised plasma-endotoxin levels from baseline to the first and subsequent treatment cycles for their cancers. Probiotics in this cohort were deemed safe and tolerable. Significant improvement in emotional QoL scores ( p = 0.015) was reported with increased number of chemotherapy cycles. In a related observational study of exceptional responders to chemotherapy, participants were found to have had a high intake of fruits, vegetables, and fibre possibly indicative of a more balanced intestinal microbiota. Conclusion: A multi-strain probiotic formulation was safe and tolerated in this chronically ill cohort that were undergoing oncological treatment. The probiotic formulation alleviated diarrhoea, constipation and maintained stool consistency/frequency during the multiple treatments with chemotherapy and radiotherapy. Intestinal dysbiosis that is characterised by decreased microbial diversity and increased pro-inflammatory species was not observed. Probiotic supplementation may have helped reduce dysbiosis during cancer treatments. These improvements may have been critical with the observation that emotional wellbeing was significantly improved from baseline. Hence albeit that the study had limitations, the probiotic intervention provided adjunctive treatment support to the patients. What is of scientifically plausible interest is that probiotics have a long association historically with human hosts and as such ratify their inclusion offering a significant adjunctive therapeutic potential. Future studies warrant larger sample sizes, control groups and should limit recruitment to a largely homogenous group of patients.Keywords
Funding Information
- University of Sydney
This publication has 34 references indexed in Scilit:
- Microbiome in Colonic Carcinogenesis2023
- Effect of probiotics and gut microbiota on anti-cancer drugs: Mechanistic perspectivesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2021
- Molecular mechanisms of postbiotics in colorectal cancer prevention and treatmentCritical Reviews in Food Science and Nutrition, 2020
- Using MicrobiomeAnalyst for comprehensive statistical, functional, and meta-analysis of microbiome dataNature Protocols, 2020
- Gut microbiome and cancer immunotherapyCancer Letters, 2019
- Factors Associated With Attrition in a Multicenter Longitudinal Observational Study of Patients With Advanced CancerJournal of Pain and Symptom Management, 2018
- Alternative method for gas chromatography‐mass spectrometry analysis of short‐chain fatty acids in faecal samplesJournal of Separation Science, 2012
- A framework for human microbiome researchNature, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbationProceedings of the National Academy of Sciences of the United States of America, 2010